Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Other solid neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Leukemia 1

Interventions

Cytarabine 465Cyclophosphamide 459fludarabine phosphate 277Rituximab 249Methotrexate 245Etoposide 203fludarabine 200Filgrastim 199Peripheral Blood Stem Cell Transplantation 180Busulfan 169Vincristine 163Dexamethasone 153Daunorubicin 151Azacitidine 145Mycophenolic Acid 142Whole-Body Irradiation 133Tacrolimus 127Imatinib Mesylate 127Cyclosporine 123Granulocyte Colony-Stimulating Factor 118Radiotherapy 113Melphalan 110Idarubicin 103Doxorubicin 101Mitoxantrone 97Decitabine 97Antilymphocyte Serum 97Lenalidomide 96Mercaptopurine 93Prednisone 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × sapacitabine × Other hematologic neoplasm × Clear all
NCT00590187 2024-06-04

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Cyclacel Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled 11 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01303796 2022-06-22

SEAMLESS

Cyclacel Pharmaceuticals, Inc.

Phase 3 Completed
482 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00380653 2021-12-13

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
47 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡